PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Subclinical prostate cancer is common in men> 50 years of age. Population-based
screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) …

Purpose We aimed to update a previously published, multi-institutional nomogram of
outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate …

Purpose Clinicopathologic features and biochemical recurrence are sensitive, but not
specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a …

Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease.
However, the current definitions of high-risk prostate cancer include a heterogeneous group …

Background Local failure after radical prostatectomy (RP) is common in patients with cancer
extending beyond the capsule. Three prospectively randomized trials demonstrated an …

Context The optimal treatment for men with high-risk localized or locally advanced prostate
cancer (PCa) remains unknown. Objective To perform a systematic review of the existing …

PURPOSE Adjuvant compared with early salvage radiation therapy (sRT) following radical
prostatectomy (RP) has not been shown to reduce progression-free survival in randomized …

Context The introduction of novel imaging modalities has increased the detection of
oligometastatic prostate cancer (PCa) recurrence, potentially justifying the use of a …

Biomarkers play a vital role in disease detection and treatment follow-up. It is important to
note that diseases in the early stage are typically treated with the greatest probability of …